Moss Adams Wealth Advisors’s Immix Biopharma IMMX Stock Holding History

Moss Adams Wealth Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,000	Closed	-$138K	–	156
2023 Q4	$138K	Hold	20,000	–	–	0.03%	117
2023 Q3	$68.4K	Hold	20,000	–	–	0.02%	117
2023 Q2	$53.8K	Sell	20,000 -78	-0.4%	-$163	0.02%	106
2023 Q1	$36.5K	Buy	20,078 +78	+0.4%	+$172	0.01%	117
2022 Q4	$45.8K	Buy	+20,000	New	+$26.7K	0.02%	125

Other funds holding IMMX

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

Moss Adams Wealth Advisors's IMMX Position: Q1 2024 in Review

Moss Adams Wealth Advisors sold out of Immix Biopharma (IMMX) in Q1 2024, closing a stake of 20,000 shares — an estimated $138K sold.

Moss Adams Wealth Advisors first reported a position in IMMX in Q4 2022 and held it in 5 quarters. The position peaked at $138K in Q4 2023. 35 funds tracked by Wall St. Rank hold IMMX as of Q1 2024.

Moss Adams Wealth Advisors reported no remaining Immix Biopharma position as of Q1 2024 after selling out during the quarter.
Moss Adams Wealth Advisors sold 20,000 Immix Biopharma shares in Q1 2024, an estimated $138K.
Moss Adams Wealth Advisors first reported a position in Immix Biopharma in Q4 2022 and held it in 5 quarters.
Moss Adams Wealth Advisors's Immix Biopharma position peaked at $138K in Q4 2023.
35 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2024.

Based on Moss Adams Wealth Advisors's 13F filing for Q1 2024, filed 7 May 2024.